MedTrace Logo

Correction of Psoriatic T Cell Signatures by Deucravacitinib

NCT05858645 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2024-06-27

No results posted yet for this study

Summary

This study aims to assess cutaneous and blood immune cell function of patients with psoriasis before and after initiation of treatment with the Tyrosine kinase 2 (TYK2) blocker, deucravacitinib.

Conditions

  • Psoriasis Vulgaris

Interventions

DRUG

deucravacitinib

Treatment with deucravacitinib, skin biopsy and blood analysis pre- and mid-treatment

Sponsors & Collaborators

Principal Investigators

  • Raymond Cho, MD, PhD · University of California, San Francisco

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-01
Primary Completion
2026-06-30
Completion
2026-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05858645 on ClinicalTrials.gov